Stay updated on Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.

Latest updates to the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page
- Check3 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedVersion 34 updates the record by renaming the study to include Placebo With ADT and adding the Contacts/Locations, Study Design, Study Status, and Study Identification sections. These changes align the study's identification with the protocol and provide essential administrative details for tracking.SummaryDifference0.5%

- Check31 days agoChange DetectedAdded Revision: v3.4.2 to the history. Removed the government funding lapse notice and operating-status guidance that previously appeared on the page.SummaryDifference0.5%

- Check38 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's status. Updated the page revision to v3.4.1, with the previous revision v3.4.0 removed.SummaryDifference0.5%

- Check45 days agoChange DetectedThe page now shows a Show glossary option and a legend for color-coded changes (green for additions, red for deletions). It also introduces the latest revision label (Revision: v3.4.0) and a minor capitalization change in 'No FEAR Act Data'.SummaryDifference0.7%

- Check59 days agoChange DetectedThe history now shows Revision: v3.3.4 and omits Revision: v3.3.3, which affects only revision history metadata and does not alter the study's core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.